Efficacy News and Research

RSS

Drugging RNA synthesis in SARS-CoV-2 as novel therapeutic avenue

In a new study, the role of a coronavirus-specific protein domain in SARS-CoV-2 viral synthesis initiation is investigated, and potential therapeutic solutions have been explored.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

New machine learning algorithm ranks drugs based on efficacy in reducing cancer cell growth

Researchers from the Queen Mary University of London have developed a machine learning algorithm that ranks drugs based on their efficacy in reducing cancer cell growth.

25 Mar 2021

Food preservative may harm the immune system, shows new study

A food preservative used to prolong the shelf life of Pop-Tarts, Rice Krispies Treats, Cheez-Its and almost 1,250 other popular processed foods may harm the immune system, according to a new peer-reviewed study by Environmental Working Group.

25 Mar 2021

Researcher to use new approach to explore brain proteins and their potential to cure mental diseases

Dr. Hans Maric has received one of the German Research Foundation's highly prestigious Emmy Noether awards, worth around 1.7 million euros.

25 Mar 2021

New therapeutic vaccine uses patient's own tumor cells to aid in cancer destruction

Immunotherapy, which recruits the body's own immune system to attack cancer, has given many cancer patients a new avenue to treat the disease.

24 Mar 2021

Repurposed heart and flu drugs that protect platelets improve survival of septic mice

Despite continued improvements in antibiotics and hospital intensive care, staph sepsis - a bloodstream infection caused by Staphylococcus aureus bacteria - still causes severe illness or death in 20 to 30 percent of patients who contract it.

24 Mar 2021

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

An international team of researchers has found that three commonly used antiviral and antimalarial drugs are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes COVID-19.

24 Mar 2021

Researchers examine acriflavine's antiviral potential against SARS-CoV-2

Acriflavine is traditionally employed as a topical antiseptic, though has more recently been implicated as an antiviral agent at low doses, potentially by stimulating the production of interferon. In a new study recently uploaded to the bioRxiv* preprint server, the application of the drug to SARS-CoV-2 infection is investigated, demonstrating a broad activity towards a range of other betacoronaviruses.

24 Mar 2021

Sargramostim drug can also improve memory in people with mild-to-moderate Alzheimer's disease

A new study suggests that Sargramostim, a medication often used to boost white blood cells after cancer treatments, is also effective in treating and improving memory in people with mild-to-moderate Alzheimer's disease.

24 Mar 2021

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

A new study adds to the sum of knowledge about SARS-CoV-2, with respect to its natural and biologically significant mutations, using computational modeling of the virus-receptor interactions. Understanding how viral mutations affect the virus-host interactions is crucial for shaping proper strategies to control the virus.

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

A new study describes the use of a combination of virtual and experimental screening protocols to identify potential inhibitors of the virus, which could lead to rapid drug development.

24 Mar 2021

Delaying second doses of COVID-19 vaccines can reduce positive cases

Delaying second doses of COVID-19 vaccines should reduce case numbers in the near term; however, the longer term case burden and the potential for evolution of viral ‘escape’ from immunity will depend on the robustness of immune responses generated by natural infections and one or two vaccine doses, according to a study from McGill University and Princeton University published today in Science.

24 Mar 2021

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

A new preprint study led by Shawn S-C. Li from Western University in Ontario, Canada, provides evidence of epitope-specific antibody responses and designed a test to measure this in relation to disease severity and outcome after infection.

24 Mar 2021

Study may lead to more refined approaches for head and neck cancers

By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from the UCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.

24 Mar 2021

SARS-CoV-2 infection after vaccination is possible, shows study

In a letter to The New England Journal of Medicine, published online March 23, 2021, a group of investigators from University of California San Diego School of Medicine and the David Geffen School of Medicine at UCLA report COVID-19 infection rates for a cohort of health care workers previously vaccinated for the novel coronavirus.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Correlation of antibody titers with COVID-19 vaccine efficacy

In a new study the relationship between virus-neutralizing antibody and spike protein-binding IgG antibody levels is explored following vaccination by one of seven currently deployed vaccines. The findings support the use of antibody titers as correlates of protection for COVID-19 vaccines.

23 Mar 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

Efficacy News and Research

Drugging RNA synthesis in SARS-CoV-2 as novel therapeutic avenue

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

New machine learning algorithm ranks drugs based on efficacy in reducing cancer cell growth

Food preservative may harm the immune system, shows new study

Researcher to use new approach to explore brain proteins and their potential to cure mental diseases

New therapeutic vaccine uses patient's own tumor cells to aid in cancer destruction

Repurposed heart and flu drugs that protect platelets improve survival of septic mice

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

Researchers examine acriflavine's antiviral potential against SARS-CoV-2

Sargramostim drug can also improve memory in people with mild-to-moderate Alzheimer's disease

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

Delaying second doses of COVID-19 vaccines can reduce positive cases

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

Study may lead to more refined approaches for head and neck cancers

SARS-CoV-2 infection after vaccination is possible, shows study

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Correlation of antibody titers with COVID-19 vaccine efficacy

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News